Distinct functions of eosinophils in severe asthma with type 2 phenotype: clinical implications

키워드

참고문헌 (103)

1. Kaur R, "Phenotypes and endotypes of adult asthma : moving toward precision medicine", J Allergy Clin Immunol, 144, pp.1~12 (2019)
2. Corren J, "Asthma phenotypes and endotypes : an evolving paradigm for classification", Discov Med, 15, pp.243~249 (2013)
3. Kuruvilla ME, "Understanding asthma phenotypes, endotypes, and mechanisms of disease", Clin Rev Allergy Immunol, 56, pp.219~233 (2019)
4. Wenzel SE, "Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics", Am J Respir Crit Care Med, 160, pp.1001~1008 (1999)
5. Carr TF, "Eosinophilic and noneosinophilic asthma", Am J Respir Crit Care Med, 197, pp.22~37 (2018)
6. Duvall MG, "Non-type 2 inflammation in severe asthma is propelled by neutrophil cytoplasts and maintained by defective resolution", Allergol Int, 68, pp.143~149 (2019)
7. Wenzel S, "Severe asthma in adults", Am J Respir Crit Care Med, 172, pp.149~160 (2005)
8. Schleich FN, "Importance of concomitant local and systemic eosinophilia in uncontrolled asthma", Eur Respir J, 44, pp.97~108 (2014)
9. Buhl R, "Severe eosinophilic asthma : a roadmap to consensus", Eur Respir J, 49, pp.1700634~ (2017)
10. Dolan CM, "Design and baseline characteristics of the epidemiology and natural history of asthma : outcomes and treatment regimens(TENOR)study : a large cohort of patients with severe or difficult-to-treat asthma", Ann Allergy Asthma Immunol, 92, pp.32~39 (2004)
11. Moore WC, "Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute’s Severe Asthma Research Program", J Allergy Clin Immunol, 119, pp.405~413 (2007)
12. Hew M, "Corticosteroid insensitivity in severe asthma : significance, mechanisms and aetiology", Intern Med J, 40, pp.323~334 (2010)
13. Chung KF, "International ERS", ATS guidelines on definition, evaluation and treatment of severe asthma, 2014, pp.43, 343~373
14. 송우정, "Future Risks in Patients With Severe Asthma", Allergy, Asthma & Immunology Research, 11(6), pp.763~778 (2019), 대한천식알레르기학회
15. Wenzel S, "Severe asthma : from characteristics to phenotypes to endotypes", Clin Exp Allergy, 42, pp.650~658 (2012)
16. Tran TN, "Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma", Ann Allergy Asthma Immunol, 116, pp.37~42 (2016)
17. Chapman KR, "The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma", Allergy, 74, pp.1716~1726 (2019)
18. Huang YC, "Endotypes of severe allergic asthma patients who clinically benefit from anti-IgE therapy", Clin Exp Allergy, 49, pp.44~53 (2019)
19. Price DB, "Blood eosinophil count and prospective annual asthma disease burden : a UK cohort study", Lancet Respir Med, 3, pp.849~858 (2015)
20. De Groot JC, "Clinical profile of patients with adult-onset eosinophilic asthma", ERJ Open Res, 2, pp.00100~2015 (2016)
21. Steinke JW, "Aspirin-exacerbated respiratory disease : pathophysiological insights and clinical advances", J Asthma Allergy, 9, pp.37~43 (2016)
22. 최영우, "Which Factors Associated With Activated Eosinophils Contribute to the Pathogenesis of Aspirin-Exacerbated Respiratory Disease?", Allergy, Asthma & Immunology Research, 11(3), pp.320~329 (2019), 대한천식알레르기학회
23. Choi Y, "Surfactant protein D alleviates eosinophil-mediated airway inflammation and remodeling in patients with aspirin-exacerbated respiratory disease", Allergy, 74, pp.78~88 (2019)
24. Choi Y, "Immunomodulatory function of surfactant protein D in eosinophilic asthma", Allergy, 74, pp.192~195 (2019)
25. Trinh HK, "Epithelial folliculin enhances airway inflammation in aspirin-exacerbated respiratory disease", Clin Exp Allergy, 48, pp.1464~1473 (2018)
26. Rosenberg HF, "Eosinophils : changing perspectives in health and disease", Nat Rev Immunol, 13, pp.9~22 (2013)
27. Pagnoux C, "Serum cytokine and chemokine levels in patients with eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, or eosinophilic asthma", Clin Exp Rheumatol, 37(Suppl 117), pp.40~44 (2019)
28. Tagaya E, "Mechanisms of airway remodeling in asthma", Allergol Int, 56, pp.331~340 (2007)
29. Acharya KR, "Eosinophil granule proteins : form and function", J Biol Chem, 289, pp.17406~17415 (2014)
30. 이영수, "Serum Levels of Eosinophil-Derived Neurotoxin: A Biomarker for Asthma Severity in Adult Asthmatics", Allergy, Asthma & Immunology Research, 11(3), pp.394~405 (2019), 대한천식알레르기학회
31. MacKenzie JR, "Eosinophils promote allergic disease of the lung by regulating CD4(+)Th2 lymphocyte function", J Immunol, 167, pp.3146~3155 (2001)
32. Mattes J, "Intrinsic defect in T cell production of interleukin(IL)-13 in the absence of both IL-5 and eotaxin precludes the development of eosinophilia and airways hyperreactivity in experimental asthma", J Exp Med, 195, pp.1433~1444 (2002)
33. Emma R, "Mepolizumab in the management of severe eosinophilic asthma in adults : current evidence and practical experience", Ther Adv Respir Dis, 12, pp.1753466618808490~ (2018)
34. Choi Y, "Neutrophil extracellular DNA traps induce autoantigen production by airway epithelial cells", Mediators Inflamm, 2017, pp.5675029~ (2017)
35. Choi Y, "Neutrophil activation in occupational asthma", Curr Opin Allergy Clin Immunol, 19, pp.81~85 (2019)
36. Yang D, "Eosinophil-derived neurotoxin acts as an alarmin to activate the TLR2-MyD88 signal pathway in dendritic cells and enhances Th2 immune responses", J Exp Med, 205, pp.79~90 (2008)
37. Elishmereni M, "Physical interactions between mast cells and eosinophils : a novel mechanism enhancing eosinophil survival in vitro", Allergy, 66, pp.376~385 (2011)
38. Brinkmann V, "Neutrophil extracellular traps kill bacteria", Science, 303, pp.1532~1535 (2004)
39. Papayannopoulos V, "Neutrophil extracellular traps in immunity and disease", Nat Rev Immunol, 18, pp.134~147 (2018)
40. Castanheira FV, "Neutrophils and NETs in modulating acute and chronic inflammation", Blood, 133, pp.2178~2185 (2019)
41. Von Kockritz-Blickwede M, "Phagocytosis-independent antimicrobial activity of mast cells by means of extracellular trap formation", Blood, 111, pp.3070~3080 (2008)
42. Webster SJ, "Distinct cell death programs in monocytes regulate innate responses following challenge with common causes of invasive bacterial disease", J Immunol, 185, pp.2968~2979 (2010)
43. Mohanan S, "Identification of macrophage extracellular trap-like structures in mammary gland adipose tissue : a preliminary study", Front Immunol, 4, pp.67~ (2013)
44. Ueki S, "Eosinophil extracellular trap cell death-derived DNA traps : their presence in secretions and functional attributes", J Allergy Clin Immunol, 137, pp.258~267 (2016)
45. Dworski R, "Eosinophil and neutrophil extracellular DNA traps in human allergic asthmatic airways", J Allergy Clin Immunol, 127, pp.1260~1266 (2011)
46. Ueki S, "Eosinophil extracellular DNA trap cell death mediates lytic release of free secretion-competent eosinophil granules in humans", Blood, 121, pp.2074~2083 (2013)
47. Yousefi S, "Eosinophil extracellular DNA traps : molecular mechanisms and potential roles in disease", Curr Opin Immunol, 24, pp.736~739 (2012)
48. Ueki S, "Eosinophil ETosis and DNA traps : a new look at eosinophilic inflammation", Curr Allergy Asthma Rep, 16, pp.54~ (2016)
49. Yousefi S, "Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense", Nat Med, 14, pp.949~953 (2008)
50. Mukherjee M, "Eosinophil extracellular traps and inflammatory pathologies-untangling the Web!", Front Immunol, 9, pp.2763~ (2018)
51. Simon D, "Eosinophil extracellular DNA traps in skin diseases", J Allergy Clin Immunol, 127, pp.194~199 (2011)
52. Gevaert E, "Extracellular eosinophilic traps in association with Staphylococcus aureus at the site of epithelial barrier defects in patients with severe airway inflammation", J Allergy Clin Immunol, 139, pp.1849~1860 (2017)
53. 최영우, "Biological function of eosinophil extracellular traps in patients with severe eosinophilic asthma", Experimental and Molecular Medicine, 50, pp.1~8 (2018), 생화학분자생물학회
54. Choi Y, "Eosinophil extracellular traps activate type 2 innate lymphoid cells through stimulating airway epithelium in severe asthma", Allergy, 75, pp.95~103 (2020)
55. Li Y, "Elevated expression of IL-33 and TSLP in the airways of human asthmatics in vivo : a potential biomarker of severe refractory disease", J Immunol, 200, pp.2253~2262 (2018)
56. Maas SLN, "Extracellular vesicles : unique intercellular delivery vehicles", Trends Cell Biol, 27, pp.172~188 (2017)
57. Raposo G, "Extracellular vesicles : a new communication paradigm", Nat Rev Mol Cell Biol, 20, pp.509~510 (2019)
58. Becker A, "Extracellular vesicles in cancer : cell-to-cell mediators of metastasis", Cancer Cell, 30, pp.836~848 (2016)
59. Choi Y, "Gut microbe-derived extracellular vesicles induce insulin resistance, thereby impairing glucose metabolism in skeletal muscle", Sci Rep, 5, pp.15878~ (2015)
60. Chaithanya Chelakkot, "Akkermansia muciniphila-derived extracellular vesicles influence gut permeability through the regulation of tight junctions", Experimental and Molecular Medicine, 50, pp.1~11 (2018), 생화학분자생물학회
61. 최영우, "Extracellular Vesicles, a Key Mediator to Link Environmental Microbiota to Airway Immunity", Allergy, Asthma & Immunology Research, 9(2), pp.101~106 (2017), 대한천식알레르기학회
62. Canas JA, "Exosomes from eosinophils autoregulate and promote eosinophil functions", J Leukoc Biol, 101, pp.1191~1199 (2017)
63. Mazzeo C, "Exosome secretion by eosinophils : a possible role in asthma pathogenesis", J Allergy Clin Immunol, 135, pp.1603~1613 (2015)
64. Akuthota P, "Extracellular microvesicle production by human eosinophils activated by"inflammatory"stimuli", Front Cell Dev Biol, 4, pp.117~ (2016)
65. Mortaz E, "Exosomes in severe asthma : update in their roles and potential in therapy", Biomed Res Int, 2018, pp.2862187~ (2018)
66. Sastre B, "Novel modulators of asthma and allergy : exosomes and microRNAs", Front Immunol, 8, pp.826~ (2017)
67. Global Strategy for Asthma Management and Prevention, 2019, "Global Initiative for Asthma", GINA, ~ (2019)
68. Wegmann M, "Targeting eosinophil biology in asthma therapy", Am J Respir Cell Mol Biol, 45, pp.667~674 (2011)
69. Adcock IM, "Molecular mechanisms of corticosteroid resistance", Chest, 134, pp.394~401 (2008)
70. Rhen T, "Antiinflammatory action of glucocorticoids : new mechanisms for old drugs", N Engl J Med, 353, pp.1711~1723 (2005)
71. Barnes PJ, "Inhaled corticosteroids", Pharmaceuticals(Basel), 3, pp.514~540 (2010)
72. Gibson PG, "Acute anti-inflammatory effects of inhaled budesonide in asthma : a randomized controlled trial", Am J Respir Crit Care Med, 163, pp.32~36 (2001)
73. Erin EM, "Rapid effect of inhaled ciclesonide in asthma : a randomized, placebo-controlled study", Chest, 134, pp.740~745 (2008)
74. Pauwels RA, "Early intervention with budesonide in mild persistent asthma : a randomised, double-blind trial", Lancet, 361, pp.1071~1076 (2003)
75. Sullivan PW, "Oral corticosteroid exposure and adverse effects in asthmatic patients", J Allergy Clin Immunol, 141, pp.110~116 (2018)
76. Liu S, "Steroid resistance of airway type 2 innate lymphoid cells from patients with severe asthma : the role of thymic stromal lymphopoietin", J Allergy Clin Immunol, 141, pp.257~268 (2018)
77. Kankaanranta H, "Add-on therapy options in asthma not adequately controlled by inhaled corticosteroids : a comprehensive review", Respir Res, 5, pp.17~ (2004)
78. Greening AP, "Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group", Lancet, 344, pp.219~224 (1994)
79. Pauwels RA, "Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group", N Engl J Med, 337, pp.1405~1411 (1997)
80. Gibson PG, "Differential effects of maintenance long-acting beta-agonist and inhaled corticosteroid on asthma control and asthma exacerbations", J Allergy Clin Immunol, 119, pp.344~350 (2007)
81. Kankaanranta H, "Delayed eosinophil apoptosis in asthma", J Allergy Clin Immunol, 106(1 Pt 1), pp.77~83 (2000)
82. Nielson CP, "Beta-adrenoceptor agonists block corticosteroid inhibition in eosinophils", Am J Respir Crit Care Med, 157, pp.184~191 (1998)
83. Calhoun WJ, "Summary of clinical trials with zafirlukast", Am J Respir Crit Care Med, 157(6 Pt 2), pp.S238~S248 (1998)
84. Knorr B, "Montelukast for chronic asthma in 6-to 14-year-old children : a randomized, double-blind trial. Pediatric Montelukast Study Group", JAMA, 279, pp.1181~1186 (1998)
85. Dempsey OJ, "Leukotriene receptor antagonist therapy", Postgrad Med J, 76, pp.767~773 (2000)
86. Thompson-Souza GA, "functional roles and therapeutic perspectives in eosinophilic disorders", Front Med (Lausanne), 4, pp.106~ (2017)
87. Helfrich S, "Group 2 innate lymphoid cells in respiratory allergic inflammation", Front Immunol, 10, pp.930~ (2019)
88. Ducharme FM, "Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma", Cochrane Database Syst Rev, 4, pp.CD003137~ (2006)
89. Kolbeck R, "MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function", J Allergy Clin Immunol, 125, pp.1344~1353 (2010)
90. Bleecker ER, "Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma", Eur Respir J, 52, pp.1800936~ (2018)
91. 박해심, "Efficacy and Safety of Benralizumab for Korean Patients With Severe, Uncontrolled Eosinophilic Asthma", Allergy, Asthma & Immunology Research, 11(4), pp.508~518 (2019), 대한천식알레르기학회
92. Albers FC, "Update : mepolizumab treatment in patients with severe eosinophilic asthma and prior omalizumab use", Allergy, 75, pp.942~946 (2020)
93. Nair P, "Mepolizumab for prednisone-dependent asthma with sputum eosinophilia", N Engl J Med, 360, pp.985~993 (2009)
94. Ortega HG, "Mepolizumab treatment in patients with severe eosinophilic asthma", N Engl J Med, 371, pp.1198~1207 (2014)
95. Castro M, "Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts : results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3trials", Lancet Respir Med, 3, pp.355~366 (2015)
96. Zhu J, "T helper 2 (Th2) cell differentiation, type 2 innate lymphoid cell (ILC2) development and regulation of interleukin-4 (IL-4) and IL-13 production", Cytokine, 75, pp.14~24 (2015)
97. Hofman FM, "IL-4 regulates differentiation and proliferation of human precursor B cells", J Immunol, 141, pp.1185~1190 (1988)
98. Wenzel S, "Dupilumab in persistent asthma with elevated eosinophil levels", N Engl J Med, 368, pp.2455~2466 (2013)
99. Castro M, "Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma", N Engl J Med, 378, pp.2486~2496 (2018)
100. Divekar R, "Recent advances in epithelium-derived cytokines(IL-33, IL-25, and thymic stromal lymphopoietin)and allergic inflammation", Curr Opin Allergy Clin Immunol, 15, pp.98~103 (2015)
101. Stolarski B, "IL-33 exacerbates eosinophil-mediated airway inflammation", J Immunol, 185, pp.3472~3480 (2010)
102. Wong CK, "Thymic stromal lymphopoietin induces chemotactic and prosurvival effects in eosinophils : implications in allergic inflammation", Am J Respir Cell Mol Biol, 43, pp.305~315 (2010)
103. Gauvreau GM, "Effects of an anti-TSLP antibody on allergen-induced asthmatic responses", N Engl J Med, 370, pp.2102~2110 (2014)